HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- #MeToo movement in medicine: ‘Community of allies’ required to end culture of sexual harassment
-
- Getting the word out: Effective communication key to ensuring informed choices John Sweetenham, MD, FRCP, FACP
- Precision immunotherapy: Giving the right drug to the right patient at the right time Razelle Kurzrock, MD; Vivek Subbiah, MD
- Addition of palbociclib to fulvestrant extends OS among certain women with advanced breast cancer
- Alpelisib prolongs PFS for PIK3CA-mutant advanced breast cancer
- Olaparib confers ‘unprecedented’ PFS benefit in ovarian cancer
- Liquid biopsy test confirms remission in HPV-associated oral cancer
- Stereotactic ablative radiotherapy for renal cell carcinoma safe in patients with solitary kidney
- Shorter trastuzumab course may be viable for some women with early HER2-positive breast cancer
-
- Use of targeted treatments for advanced cancer increasing in community setting
- Vandetanib shows promise for advanced thyroid cancer
- Women more likely to experience key side effects from chemotherapy for esophagogastric cancer
- SD-101 plus pembrolizumab induces response in recurrent, metastatic head and neck cancer
- Sarcoma treatments evolve as understanding of disease biology improves
- Triple combination appears safe, effective for advanced BRAF V600-mutant melanoma
- Nivolumab benefit in advanced head and neck cancer maintained regardless of age
- Immune-related adverse events manageable with vigilance, appropriate treatment
-
- Second-line therapy for myelofibrosis remains ‘active area of research’
- Cognitive computing platform may help oncologists deliver subspecialist-level care
- Ribociclib-fulvestrant combination extends PFS for certain postmenopausal women with breast cancer
- More research needed to realize true benefit of PARP inhibitors in breast cancer
- Denosumab effective in transfusion-dependent thalassemia-induced osteoporosis
- Dabrafenib-trametinib combination shows durable RFS benefit in BRAF V600-mutant melanoma
- Variant reclassifications ‘common’ after hereditary cancer genetic testing
- Black women more likely to skip breast cancer treatment
-
- FDA announces new steps to curb youth tobacco use
- FDA approves pembrolizumab for hepatocellular carcinoma, lung cancer indications
- FDA grants priority review to Tecentriq combination for advanced triple-negative breast cancer
- FDA approves Udenyca, biosimilar to pegfilgrastim, for patients receiving myelosuppressive chemotherapy
- FDA grants priority review to Lynparza for maintenance therapy of BRCA-positive ovarian cancer
- FDA approves triplet regimen for relapsed, refractory myeloma
- FDA grants fast track designation to selinexor for relapsed or refractory diffuse large B-cell lymphoma
- FDA grants priority review to Jakafi for acute graft-versus-host disease
-
- FDA grants priority review to Lonsurf for advanced gastric adenocarcinoma
- FDA approves Khapzory for injection
- Arti Hurria, MD, remembered as ‘true giant’ in oncology, tireless advocate for patients
- Five individuals receive American Cancer Society Medal of Honor
- Four elected to ASH executive committee
- Rutgers Cancer Institute section chief receives distinguished service award
- Yale Cancer Center names neuro-oncology chief